Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663493 | 0.83 | CTSC (0.48) | CTSCTSHRSMN1; SMN2MEN1HTT | |
| SCHEMBL8904491 | 0.80 | PTGES (0.43) | CTSSCTSK | |
| SCHEMBL4837691 | 0.79 | CTSC (0.49) | CTSCTSHRSMN1; SMN2MEN1HTT | |
| SCHEMBL28652466 | 0.78 | SMN1; SMN2 (0.54) | CTSCTSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL9613415 | 0.76 | CNR2 (0.49) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL8903502 | 0.76 | TSHR (0.49) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL4397838 | 0.75 | TSHR (0.45) | CTSCTSHRSMN1; SMN2MEN1HTT | |
| SCHEMBL8903139 | 0.75 | CTSS (0.49) | CTSCCTSSCTSK | |
| SCHEMBL1709301 | 0.75 | TSHR (0.47) | CTSCTSHRSMN1; SMN2MEN1HTT | |
| SCHEMBL1709334 | 0.75 | TSHR (0.47) | CTSCTSHRSMN1; SMN2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188494-A1 | Use Of 5-Alkyl-6-Phenylalkyl-7-Aminoazolopyrimidines, Novel Azolopyrimidines, Processes For Their Preparation And Compositions Comprising Them | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| EP-1876899-A2 | USE OF 5-ALKYL-6-PHENYLALKYL-7-AMINO-AZOLOPYRIMIDINES, NOVEL AZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND AGENTS CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114405-A2 | USE OF 5-ALKYL-6-PHENYLALKYL-7-AMINO-AZOLOPYRIMIDINES, NOVEL AZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND AGENTS CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188494-A1 | Use Of 5-Alkyl-6-Phenylalkyl-7-Aminoazolopyrimidines, Novel Azolopyrimidines, Processes For Their Preparation And Compositions Comprising Them | RRM2, PNP, NT5C3B | CTSC 4042/4885TSHR 2280/4885SMN1; SMN2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.